STOCKHOLM, Aug. 19, 2021 /PRNewswire/ The second quarter in figures Net sales amounted to TSEK 2,258 (1,683). The loss after tax amounted to TSEK 11,151 (8,864). The loss per share amounted
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma
News provided by
Share this article
Share this article
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and other unmet clinical indications, today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational New Drug (IND) application for the company s lead candidate, STP705, for the treatment of skin squamous cell carcinoma
in situ (isSCC).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
oncology pipeline at 2021 ASCO Meeting
Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer
Data that reinforce Libtayo (cemiplimab-rwlc) as a standard of care in advanced non-melanoma skin cancer and advanced non-small cell lung cancer, including new data in historically underrepresented patients with brain metastases
Longer term data and new analyses for Sarclisa (isatuximab-irfc) further strengthen efficacy profile, including for elderly patients and patients with high-risk cytogenetic abnormalities
PARIS
, 20
21 - New research being presented at the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8 highlights Sanofi s transformative science and commitment to patient care across difficult-to-treat cancers, including mu
American Skin Association Announces 2021 Research Grants for Skin Cancer and Diseases
News provided by
Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ American Skin Association has announced the awarding of two coveted research grants under the
ASA Milstein Research Scholar Awards program
.
ASA Milstein Research Scholar Award for Melanoma/Non-Melanoma Skin Cancer and
Ester Del Duca, MD of the Icahn School of Medicine at Mount Sinai received the
ASA Milstein Research Scholar Award in Atopic Dermatitis.
This year of grants includes the
ASA Daneen & Charles Stiefel Investigative Scientist Award in Melanoma Research awarded to
Elena Piskonouva, PhD of Weill Cornell Medicine. The Stiefel Family, longtime supporters of ASA, generously contributed $300,000 to support grants for melanoma research. The purpose of this funding is to identify and support emerging leaders in dermatology focused on melanoma research. Specifically catering to mid-ca